Gestational Exposure to NSAIDs Tied to Childhood Chronic Kidney Disease
MONDAY, Jan. 6, 2025 -- Gestational exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk for childhood chronic kidney disease (CHD), although the association is not seen in sibling comparisons, according to a study published online Dec. 23 in JAMA Pediatrics.
You-Lin Tain, M.D., Ph.D., from Kaohsiung Chang Gung Memorial Hospital and the Chang Gung University College of Medicine in Taiwan, and colleagues examined the association between gestational exposure to NSAIDs and the risk for CKD in childhood in a cohort study involving 1,025,255 children born alive in Taiwan from Jan. 1, 2007, to Dec. 31, 2017, with follow-up until Dec. 31, 2021.
The study included 163,516 singleton-born children whose mothers used at least one dispensing of an NSAID during pregnancy. The researchers observed a significant association between gestational NSAID exposure and a higher risk for childhood CKD (weighted hazard ratio [wHR], 1.10). In sibling comparisons, there was no association seen between NSAID use and fetal nephrotoxicity. In singleton-born children, increased risks were seen for exposure during the second and third trimesters (wHRs, 1.19 and 1.12, respectively). Specific NSAID exposures associated with elevated CKD risk included indomethacin and ketorolac in the first trimester (wHRs, 1.69 and 1.28, respectively); diclofenac and mefenamic acid in the second trimester (wHRs, 1.27 and 1.29, respectively); and ibuprofen in the third trimester (wHR, 1.34).
"Future research should investigate the specific roles of genetic and environmental factors in kidney development across different stages of pregnancy," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Guidance Issued on Impact, Management of Potassium, Phosphorus in CKD
THURSDAY, Sept. 25, 2025 -- Guidance is presented for understanding the impact of potassium and phosphorus additives on people with chronic kidney disease (CKD) and managing their...
Machine, Deep Learning Models Improve Prediction of CKD Progression
MONDAY, Sept. 15, 2025 -- Machine learning and deep learning models applied to integrated clinical and claims data can improve prediction of chronic kidney disease (CKD)...
Baxdrostat Reduces Seated Systolic BP in Uncontrolled, Resistant Hypertension
MONDAY, Sept. 8, 2025 -- The addition of baxdrostat, an aldosterone synthase inhibitor, to background therapy yields a significant reduction in seated systolic blood pressure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.